Detection method for human pappilomavirus (HPV) and its application in cervical cancer

Abstract

Embodiments of the invention provide methods, assays, and kits for detecting HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with pre-malignant and malignant epithelial cell lesions. Detection of HPV DNAs, genomes, and / or oncoproteins by nucleic acid hybridization assays and immunological assays can be used in early clinical screening for HPV infection and diagnosis for cervical cancer. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of co-pending U.S. patent application Ser. No. 11 / 559,366, filed Nov. 13, 2006, which claims benefit of U.S. provisional patent application Ser. No. 60 / 737,152, filed Nov. 15, 2005. Each of the aforementioned related patent applications is herein incorporated by reference.BACKGROUND OF THE INVENTION[0002]Cancer of the uterine cervix or cervical cancer is the second most common cancer in women worldwide. Although screening programs to identify precursor lesions of cervical cancer have contributed to a reduction in mortality and morbidity, 500,000 new cases of invasive cervical cancer are diagnosed worldwide and 230,000 women die of cervical cancer annually. Early detection and diagnosis is critical for survival of cervical cancer.[0003]Infection by human papillomaviruses (HPV) at specific epithelium cells to induce epithelial proliferations plays an important role for cervical carcinogenesis. About 99 per...

AI Technical Summary

Problems solved by technology

The presence of these lesions, preferentially observed in women aged 35-40 yrs, are at high risk of progression toward invasive cancer.

However, the development of cervical cancer is a multiple step process that cannot be explained simply by infection with specific types of HPV.

It is found that younger age group women are often infected with HPV; however, clinical information reveals that most latent or asymptomatic infections with high risk HPV types as well as early dysplastic lesions (CIN 1) are usually self-limited and regress spontaneously.

However, due to subjective test criteria, drawbacks of pap smear tests include difficulty in obtaining samples, poor inter- and intra-observer agreement, a high rate of false negatives (up to 20%) and false positive, the requirements for specialized labs staffed with highly trained personnel, and inability to identify a large proportion of HPV-infected persons.

Nucleic acid methods, such as “DNA Hybrid Capture”, have been developed, but are not ideal primarily due to their high cost, assay operation procedures, and the requirements for facility, equipment, and highly trained personnel.

Attempts to detect the presence of HPV related antibodies in a human subject by ELISA (enzyme linked immunoabsorbent assays) generally lead to extremely low assay sensitivity and thus can not be developed into a commercially suitable diagnostic test.

Thus, there is no successful ELISA assay available as a diagnostic tool for clinical samples.

Images